OSE Open To Partners For Late-Stage Assets
CEO Nicolas Poirier talked to Scrip about the development plans for two late-stage assets: a therapeutic cancer vaccine and an IL-7 antagonist for ulcerative colitis.
CEO Nicolas Poirier talked to Scrip about the development plans for two late-stage assets: a therapeutic cancer vaccine and an IL-7 antagonist for ulcerative colitis.